Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Jun 18, 2026, 10:01 ET

      Share this article

      Share this article


      The growth of the chronic inflammatory demyelinating polyneuropathy market is expected to be primarily driven by an expanding diagnosed patient population, improved disease awareness and diagnostic rates, increasing treatment uptake of immunoglobulin and targeted biologics, and the anticipated introduction of novel mechanism-based therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), Empasiprubart (argenx), NVG-2089 (Nuvig Therapeutics), DNTH103 (Dianthus Therapeutics), TAK-881 and TAK-411 (Takeda), and others.

      LAS VEGAS, June 18, 2026 /PRNewswire/ -- Recently published Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

      Chronic Inflammatory Demyelinating Polyneuropathy Market Summary

      • The total chronic inflammatory demyelinating polyneuropathy treatment market size is expected to grow positively by 2036 in the leading markets.
      • The United States accounted for the largest chronic inflammatory demyelinating polyneuropathy treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
      • The prevalence of CIDP is estimated to be around 5-7 cases per 100,000 individuals in the UK.
      • Leading chronic inflammatory demyelinating polyneuropathy companies, such as Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, Takeda, and others, are developing new chronic inflammatory demyelinating polyneuropathy treatment drugs that can be available in the chronic inflammatory demyelinating polyneuropathy market in the coming years. 
      • The promising chronic inflammatory demyelinating polyneuropathy therapies in clinical trials include Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, TAK-411, and others.

      Discover how big is the chronic inflammatory demyelinating polyneuropathy market @ https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

      Key Factors Driving the Growth of the Chronic Inflammatory Demyelinating Polyneuropathy Market 

      • Rising Prevalence and Improved Diagnosis of CIDP: Increasing awareness among neurologists and healthcare professionals has led to earlier and more accurate diagnosis of CIDP. Advancements in diagnostic techniques, including electrophysiological testing, imaging technologies, and biomarker research, are improving disease identification, thereby expanding the treatable patient population.
      • Growing Demand for Advanced Therapies: The market is witnessing increased demand for targeted and long-acting therapies that offer improved efficacy, reduced relapse rates, and enhanced patient convenience. Novel immunotherapies, subcutaneous immunoglobulin (SCIG) formulations, FcRn inhibitors, monoclonal antibodies, and complement-targeted therapies are gaining attention as alternatives to traditional intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange.
      • Increasing Adoption of Immunoglobulin Therapies: Immunoglobulin therapies remain the standard of care for CIDP treatment, and their continued adoption is contributing substantially to market growth. The availability of both intravenous and subcutaneous formulations has improved treatment accessibility and patient compliance.
      • Expanding Research and Development Activities: Pharmaceutical and biotechnology companies are significantly investing in research and development to introduce innovative therapies for CIDP. The growing clinical pipeline of therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), Empasiprubart (argenx), NVG-2089 (Nuvig Therapeutics), DNTH103 (Dianthus Therapeutics), TAK-881 and TAK-411 (Takeda), and others, along with increased regulatory support for rare neurological disorders, is expected to accelerate market expansion over the coming years.

      Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the CIDP treatment still faces challenges, as many current therapies have safety concerns and a slow onset of action. Older medication classes often come with troublesome side effects, highlighting the need for safer and more effective options. Encouragingly, new therapies in development offer hope for significant advancements in managing CIDP.

      Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

      • The primary objective of treatment in CIDP is to suppress immune-mediated demyelination, prevent irreversible axonal damage, restore motor and sensory function, and maintain long-term disease remission while minimizing therapy-associated adverse effects. 
      • As CIDP is a chronic autoimmune neuropathy characterized by relapsing or progressive peripheral nerve injury, treatment strategies primarily focus on modulating the dysregulated immune response underlying nerve damage.
      • Standard first-line treatment options include corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange (PLEX), each acting through distinct immunomodulatory mechanisms. 
      • Corticosteroids, including prednisone and dexamethasone, help reduce inflammatory activity and are generally initiated at higher doses followed by gradual tapering once clinical improvement or disease stabilization is achieved.
      • Subcutaneous immunoglobulin (SCIg) has increasingly become an important maintenance therapy option due to its ability to provide stable immunoglobulin levels, enable home-based administration, and improve patient convenience and quality of life. 
      • Currently approved therapies include SCIg products such as HYQVIA and FcRn inhibitors such as VYVGART Hytrulo, which are indicated for maintenance treatment or relapse prevention in adults with CIDP. 
      • Plasma exchange, which removes circulating pathogenic autoantibodies and immune complexes, may induce rapid symptomatic improvement and is particularly beneficial in severe or treatment-refractory cases, although therapeutic benefits are often temporary.
      • Treatment selection is guided by disease severity, progression, and patient comorbidities. Patients with mild disease may benefit from supportive measures such as rehabilitation, physiotherapy, and lifestyle modifications, whereas moderate-to-severe CIDP generally requires immunomodulatory intervention. 
      • Additionally, several emerging therapies are advancing through clinical development, including Riliprubart from Sanofi, Batoclimab from Immunovant, and Claseprubart (DNTH103) from Dianthus Therapeutics, all of which are being investigated for their potential to enhance disease control and reduce relapse frequency.

      Chronic Inflammatory Demyelinating Polyneuropathy Competitive Landscape

      Some of the CIDP drugs under development include Riliprubart (Sanofi), Batoclimab (Immunovant), Empasiprubart (argenx), NVG-2089 (Nuvig Therapeutics), DNTH103 (Dianthus Therapeutics), TAK-881 and TAK-411 (Takeda), and others.

      Sanofi's Riliprubart (SAR445088) is a potential first-in-class IgG4 humanized monoclonal antibody designed to selectively inhibit activated C1s within the classical complement pathway of the innate immune system. By targeting C1s, the therapy may suppress key inflammatory processes involved in demyelination and axonal injury in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The drug is administered via a convenient subcutaneous route and is currently undergoing Phase III clinical evaluation for the treatment of CIDP.

      Immunovant's Batoclimab is a human monoclonal antibody targeting the neonatal Fc receptor (FcRn), with potential immunomodulatory effects. It binds to FcRn at the IgG binding site, blocking the interaction between FcRn and immunoglobulin G (IgG). This inhibition prevents FcRn-mediated IgG recycling, promotes IgG degradation, and reduces IgG-driven inflammatory activity. Since IgG plays a central role in several autoimmune disorders, including CIDP, batoclimab may help mitigate disease-associated inflammation.

      In March 2025, Immunovant announced topline results from its Phase IIb trial of batoclimab in CIDP, reporting clinically meaningful improvements in disability scores during the initial 12-week treatment period. Notably, patients who achieved greater reductions in IgG levels demonstrated higher response rates.

      The anticipated launch of these emerging therapies are poised to transform the chronic inflammatory demyelinating polyneuropathy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic inflammatory demyelinating polyneuropathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about what drugs are in development for CIDP @ Chronic Inflammatory Demyelinating Polyneuropathy Drugs 

      Recent Developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market

      • In April 2026, argenx presented data on VYVGART (IV and SC/Hytrulo formulations) along with pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology Annual Meeting.
      • In March 2026, Dianthus Therapeutics announced an early GO decision following an interim responder analysis in the Phase 3 CAPTIVATE trial evaluating claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
      • In June 2025, Sanofi reported that the Ministry of Health, Labour and Welfare (MHLW) in Japan granted orphan drug designation (ODD) to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for people with CIDP.

      What is Chronic Inflammatory Demyelinating Polyneuropathy?

      Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune neurological disorder in which the body's immune system mistakenly attacks the myelin sheath, the protective covering surrounding peripheral nerves. This damage disrupts nerve signal transmission, leading to progressive weakness, impaired motor function, sensory loss, numbness, tingling, and reduced reflexes, typically affecting the arms and legs. CIDP can develop gradually over weeks to months and may follow either a relapsing-remitting or steadily progressive course. Although the exact cause remains unclear, early diagnosis and treatment with therapies such as corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange can help manage symptoms, improve nerve function, and prevent long-term disability.

      Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

      The chronic inflammatory demyelinating polyneuropathy epidemiology section provides insights into the historical and current chronic inflammatory demyelinating polyneuropathy patient pool and forecasted trends for the leading markets. Epidemiologic rates of CIDP are higher among males vs. females aged ≥55 years, distinguishing CIDP from other autoimmune diseases, which are typically more prevalent in women across the lifespan.

      The chronic inflammatory demyelinating polyneuropathy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

      • Total Prevalent Cases of CIDP
      • Total Diagnosed Prevalent Cases of CIDP
      • Gender-specific Diagnosed Prevalent Cases of CIDP
      • Subtype-specific Diagnosed Prevalent Cases of CIDP
      • Comorbidity-specific Diagnosed Prevalent Cases of CIDP
      • Total Treated Cases of CIDP

      Chronic Inflammatory Demyelinating Polyneuropathy Market Report Metrics

      Details

      Study Period

      2022–2036

      Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

      Total Prevalent Cases of CIDP, Total Diagnosed Prevalent Cases of CIDP, Gender-specific Diagnosed Prevalent Cases of CIDP, Subtype-specific Diagnosed Prevalent Cases of CIDP, Comorbidity-specific Diagnosed Prevalent Cases of CIDP, and Total Treated Cases of CIDP

      Key Chronic Inflammatory Demyelinating Polyneuropathy Companies

      Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, Takeda, and others

      Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies

      Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, TAK-411, HYQVIA, VYVGART Hytrulo, and others

      Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

      • Chronic Inflammatory Demyelinating Polyneuropathy Patient Population Forecast
      • Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size
      • Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis
      • Chronic Inflammatory Demyelinating Polyneuropathy Market Size and Trends
      • Chronic Inflammatory Demyelinating Polyneuropathy Market Opportunity
      • Chronic Inflammatory Demyelinating Polyneuropathy Market Unmet Needs
      • KOL's Views on Chronic Inflammatory Demyelinating Polyneuropathy
      • Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

      Download the report to understand what drugs are in development for CIDP @ Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

      Table of Contents

      1

      Chronic Inflammatory Demyelinating Polyneuropathy Market Key Insights

      2

      Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

      3

      CIDP Market Overview at a Glance

      3.1

      Market Share (%) Distribution of CIDP by Therapies in 2022 in the 7MM

      3.2

      Market Share (%) Distribution of CIDP by Therapies in 2036 in the 7MM

      4

      Methodology of Epidemiology and Market

      5

      Executive Summary

      6

      Key Events

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      Signs and Symptoms

      7.3

      Causes

      7.4

      Related Conditions

      7.5

      Etiology

      7.6

      Risk Factors

      7.7

      Pathophysiology

      7.8

      Complications

      7.9

      Diagnosis

      7.10

      Management and Treatment

      8

      Epidemiology and Patient Population

      8.1.

      Key Findings

      8.2.

      Methodology of Epidemiology

      8.3.

      Assumptions and Rationale: the 7MM

      8.3.1.

      The US

      8.3.2.

      EU4 and the UK

      8.3.3.

      Japan

      8.3

      Total Diagnosed Prevalent Cases of CIDP in the 7MM

      8.4

      The US

      8.4.1

      Total Prevalent Cases of CIDP in the US

      8.4.2

      Total Diagnosed Prevalent Cases of CIDP in the US

      8.4.3

      Subtype-specific Diagnosed Prevalent Cases of CIDP in the US

      8.4.4

      Gender-specific Diagnosed Prevalent Cases of CIDP in the US

      8.4.5

      Comorbidity-specific Diagnosed Prevalent Cases of CIDP in the US

      8.4.6

      Treated Cases of CIDP in the US

      8.5

      EU4 and the UK

      8.6

      Japan

      9

      Patient Journey

      10

      Marketed CIDP Therapies

      10.1.

      Key Cross Competition

      10.2.

      HYQVIA: Takeda

      10.2.1.

      Product Description

      10.2.2.

      Regulatory Milestones

      10.2.3.

      Other Developmental Activities

      10.2.4.

      Clinical Trials Information

      10.2.5.

      Safety and Efficacy

      10.2.6.

      Analyst Views

      10.3.

      VYVGART Hytrulo: Argenx

      List to be continued in the final report…

      11

      Emerging CIDP Drugs

      11.1

      Key Cross Competition

      11.2

      Riliprubart: Sanofi

      11.2.1

      Product Description

      11.2.2

      Other Developmental Activities

      11.2.3

      Clinical Trials Information

      11.2.4

      Safety and Efficacy

      11.2.5

      Analysts' View

      11.3

      Batoclimab: Immunovant

      List to be continued in the final report…

      12

      CIDP: Market Analysis

      12.1

      Key Findings

      12.2

      Key CIDP Market Forecast Assumptions

      12.3

      Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

      12.4

      Attribute Analysis

      12.5

      Total Market Size of CIDP in the 7MM

      12.6

      Total Market Size of CIDP by Therapies in the 7MM

      12.7

      Market Size of CIDP in the US

      12.7.1

      Total Market Size of CIDP

      12.7.2

      The Market Size of CIDP by Therapies

      12.8

      Market Size of CIDP in EU4 and the UK

      12.9

      Market Size of CIDP in Japan

      13

      Key Opinion Leaders' Views

      14

      Unmet Needs

      15

      SWOT Analysis

      16

      Market Access and Reimbursement

      16.1

      The United States

      16.2

      In EU4 and the UK

      16.3

      Japan

      17

      Bibliography

      18

      Acronyms and Abbreviations

      19

      CIDP Report Methodology

      Related Reports

      FcRn Inhibitors Market

      FcRn Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key FcRn inhibitors companies, including Immunovant, Viridian Therapeutics, argenx, UCB, Johnson & Johnson, and others.

      Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial Analysis 

      Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CIDP companies, including Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, Takeda, and others.

      Guillain-Barré Syndrome Market

      Guillain-Barré Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Guillain-Barré syndrome companies, including Annexon, Hansa Biopharma, Grifols, CSL Behring, Octapharma, Takeda, Kedrion Biopharma, and others.

      Guillain-Barré Syndrome Clinical Trial Analysis

      Guillain-Barré Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Guillain-Barré syndrome companies, including Annexon, Hansa Biopharma, Grifols, CSL Behring, Octapharma, Takeda, Kedrion Biopharma, and others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]
      +14699457679
      www.delveinsight.com

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.